Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.62
+0.05003.18%
Volume:16.70K
Turnover:27.24K
Market Cap:4.38M
PE:-0.09
High:1.69
Open:1.61
Low:1.57
Close:1.57
52wk High:41.20
52wk Low:1.52
Shares:2.70M
Float Shares:1.30M
Volume Ratio:0.73
T/O Rate:1.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.5946
EPS(LYR):-30.9580
ROE:-27725.96%
ROA:-31.66%
PB:-2.08
PE(LYR):-0.05

Loading ...

HCW Biologics Secures $4M Through Warrant Exercise

TIPRANKS
·
Nov 21

HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants

Reuters
·
Nov 21

BRIEF-Hcw Biologics Announces Warrant Inducement Agreement

Reuters
·
Nov 19

HCW Biologics Inc - Announces Warrant Inducement Agreement

THOMSON REUTERS
·
Nov 19

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire
·
Nov 19

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

GlobeNewswire
·
Nov 18

HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate

Benzinga
·
Nov 15

HCW Biologics Unveils Promising Preclinical Data for Next-Gen Immune Checkpoint Inhibitor HCW11-040

Reuters
·
Nov 10

HCW Biologics announces data presented for TCE Program based on TRBC platform

TIPRANKS
·
Nov 07

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

GlobeNewswire
·
Nov 07

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

GlobeNewswire
·
Oct 22

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

GlobeNewswire
·
Oct 16

HCW Biologics Granted Nasdaq Extension to Regain Compliance with Listing Rules

Reuters
·
Oct 16

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

GlobeNewswire
·
Sep 30

Press Release: HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

Dow Jones
·
Sep 18

HCW Biologics’ Innovative Lead Candidate HCW11-040 Boosts Cancer Therapy Potential

TIPRANKS
·
Sep 18

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

GlobeNewswire
·
Sep 16

Consumer Sentiment, Oil Inventory Reports Set for Release as US Futures Little Changed in Friday's Premarket Session

MT Newswires Live
·
Sep 12

Top Premarket Gainers

MT Newswires Live
·
Sep 12

Why Is HCW Biologics Stock Surging 102% Overnight?

Benzinga
·
Sep 12